secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001140361-25-030400
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Grace Therapeutics reports Q1 net loss $3.4M; submits GTx-104 NDA to FDA
------------------------------------------------------------------------

- Net loss $3.4M ($0.21/sh) vs $2.6M ($0.24/sh) in prior-year quarter; R&D down $1.8M to $0.9M.
- Submitted NDA to FDA for GTx-104 (IV nimodipine) for aneurysmal subarachnoid hemorrhage; based on positive STRIVE-ON Phase 3 trial.
- STRIVE-ON met primary endpoint: 19% reduction in clinically significant hypotension vs oral nimodipine; 54% patients had ≥95% relative dose intensity.
- Cash and equivalents $20.0M; potential warrant exercises of $22.6M ($7.6M + $15.0M) could extend runway into Q2 2027.
- Deprioritized GTx-102 and GTx-101 to focus on GTx-104; may license or sell those assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000114036125030400/0001140361-25-030400-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000114036125030400/ef20053073_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-030400

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer